COVID-19

Showing NaN - NaN of 31

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2 (Omi XBB.1.5))

Not yet recruiting
  • SARS-CoV-2 Infection
  • COVID-19
  • BNT162b2 (Omi XBB.1.5)
  • Dublin, California
  • +14 more
Aug 10, 2023

COVID-19 Trial in United States (XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose))

Not yet recruiting
  • COVID-19
  • XBB.1.5 Vaccine (Booster)
  • XBB.1.5 Vaccine (single dose)
  • Mobile, Alabama
  • +29 more
Aug 4, 2023

COVID-19 Trial in United States (NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant)

Active, not recruiting
  • COVID-19
  • NVX-CoV2373
  • SARS-CoV-2 rS antigen/Matrix-M Adjuvant
  • Austin, Texas
  • +4 more
May 16, 2023

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

Not yet recruiting
  • COVID-19
  • Diabete Mellitus
  • Measure of physiologic parameters
  • San Antonio, Texas
    Texas Diabetes Institute - University Health System
May 17, 2023

COVID-19 Trial in Canada, United Kingdom, United States (mRNA-1283.222, mRNA-1273.222)

Recruiting
  • COVID-19
  • mRNA-1283.222
  • mRNA-1273.222
  • Birmingham, Alabama
  • +209 more
Apr 13, 2023

SARS-CoV2 Infection, Covid19, SARS-CoV-2 Acute Respiratory Disease Trial in Worldwide (BNT162b2, BNT162b2 (B.1.1.7 + B.1.617.2),

Active, not recruiting
  • SARS-CoV2 Infection
  • +3 more
  • BNT162b2
  • +5 more
  • Long Beach, California
  • +34 more
Jan 10, 2023

COVID-19 Trial in Worldwide (AZD7442, Placebo)

Active, not recruiting
  • COVID-19
  • Birmingham, Alabama
  • +85 more
Nov 25, 2022

COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor Trial in Brazil, Mexico, United States (Cannabidiol,

Terminated
  • COVID-19
  • +2 more
  • Cannabidiol, pharmaceutically produced with < 5 ppm THC
  • Placebo
  • Phoenix, Arizona
  • +19 more
Dec 12, 2022

COVID-19 Trial in United Kingdom, United States (AZD7442, Placebo)

Completed
  • COVID-19
  • Guntersville, Alabama
  • +56 more
Oct 24, 2022

COVID-19 Trial in Puerto Rico, United States (Convalescent Plasma, Masked Saline Placebo)

Terminated
  • COVID-19
  • Convalescent Plasma
  • Masked Saline Placebo
  • Birmingham, Alabama
  • +23 more
Sep 9, 2022

COVID-19 Trial in United States (Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2

Recruiting
  • COVID-19
  • Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
  • +3 more
  • Little Rock, Arkansas
  • +24 more
Aug 2, 2022

COVID-19 Trial in Worldwide (SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent), SARS-CoV-2 adjuvanted recombinant

Active, not recruiting
  • COVID-19
  • SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent)
  • +2 more
  • Birmingham, Alabama
  • +93 more
Jul 22, 2022

COVID-19 Trial in Korea, Republic of, United States (biological, other, drug)

Completed
  • COVID-19
  • Lenzilumab
  • +2 more
  • Birmingham, Alabama
  • +55 more
Jul 21, 2022

COVID-19 Trial in Worldwide (PF-07321332, Ritonavir, Placebo)

Active, not recruiting
  • COVID-19
  • Pelham, Alabama
  • +336 more
Jul 21, 2022

COVID-19, SARS-CoV-2 Trial in Chile, Peru, United States (AZD1222, Placebo)

Active, not recruiting
  • COVID-19
  • SARS-CoV-2
  • AZD1222
  • Placebo
  • Phoenix, Arizona
  • +83 more
Jul 13, 2022

COVID-19, SARS-CoV-2 Infection Trial in United States (NVX-Cov2373)

Active, not recruiting
  • COVID-19
  • SARS-CoV-2 Infection
  • Long Beach, California
  • +30 more
Jul 18, 2022

SARS-CoV-2 Infection, COVID-19 Trial in Worldwide (BNT162b2, Placebo, BNT162b2 OMI)

Recruiting
  • SARS-CoV-2 Infection
  • COVID-19
  • BNT162b2
  • +4 more
  • Athens, Alabama
  • +158 more
Jul 18, 2022

COVID-19 Trial in Worldwide (Baricitinib, Dexamethasone, Placebo)

Completed
  • COVID-19
  • Birmingham, Alabama
  • +71 more
Jun 22, 2022

From Coronavirus Disease 2019 Vaccinated Adults and Adolescents

Terminated
  • COVID-19
    • Boston, Massachusetts
    • +31 more
    Mar 24, 2022

    Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection Trial in United States (20-valent pneumococcal conjugate vaccine (20vPnC),

    Completed
    • Pneumococcal Disease
    • +2 more
    • 20-valent pneumococcal conjugate vaccine (20vPnC)
    • +2 more
    • Anaheim, California
    • +28 more
    Mar 23, 2022

    COVID-19 Trial in Worldwide (Placebo, Remdesivir)

    Completed
    • COVID-19
    • Birmingham, Alabama
    • +59 more
    Mar 9, 2022

    COVID-19 Trial in Worldwide (Interferon beta-1a, Placebo, Remdesivir)

    Completed
    • COVID-19
    • Interferon beta-1a
    • +2 more
    • Birmingham, Alabama
    • +63 more
    Mar 9, 2022